These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 24170770)
1. Plastin polymorphisms predict gender- and stage-specific colon cancer recurrence after adjuvant chemotherapy. Ning Y; Gerger A; Zhang W; Hanna DL; Yang D; Winder T; Wakatsuki T; Labonte MJ; Stintzing S; Volz N; Sunakawa Y; Stremitzer S; El-Khoueiry R; Lenz HJ Mol Cancer Ther; 2014 Feb; 13(2):528-39. PubMed ID: 24170770 [TBL] [Abstract][Full Text] [Related]
2. A common gene variant in PLS3 predicts colon cancer recurrence in women. Szkandera J; Winder T; Stotz M; Weissmueller M; Langsenlehner T; Pichler M; Samonigg H; Renner W; Gerger A; Absenger G Tumour Biol; 2013 Aug; 34(4):2183-8. PubMed ID: 23549633 [TBL] [Abstract][Full Text] [Related]
3. Integrin genetic variants and stage-specific tumor recurrence in patients with stage II and III colon cancer. Bohanes P; Yang D; Loupakis F; LaBonte MJ; Gerger A; Ning Y; Lenz C; Lenz F; Wakatsuki T; Zhang W; Benhaim L; El-Khoueiry A; El-Khoueiry R; Lenz HJ Pharmacogenomics J; 2015 Jun; 15(3):226-34. PubMed ID: 25487679 [TBL] [Abstract][Full Text] [Related]
4. Pharmacogenetic predictors of outcome in patients with stage II and III colon cancer treated with oxaliplatin and fluoropyrimidine-based adjuvant chemotherapy. Custodio A; Moreno-Rubio J; Aparicio J; Gallego-Plazas J; Yaya R; Maurel J; Rodríguez-Salas N; Burgos E; Ramos D; Calatrava A; Andrada E; Díaz-López E; Sánchez A; Madero R; Cejas P; Feliu J Mol Cancer Ther; 2014 Sep; 13(9):2226-37. PubMed ID: 24980946 [TBL] [Abstract][Full Text] [Related]
5. Common cancer stem cell gene variants predict colon cancer recurrence. Gerger A; Zhang W; Yang D; Bohanes P; Ning Y; Winder T; LaBonte MJ; Wilson PM; Benhaim L; Paez D; El-Khoueiry R; El-Khoueiry A; Kahn M; Lenz HJ Clin Cancer Res; 2011 Nov; 17(21):6934-43. PubMed ID: 21918173 [TBL] [Abstract][Full Text] [Related]
6. Polymorphisms in VEGF and IL-8 predict tumor recurrence in stage III colon cancer. Lurje G; Zhang W; Schultheis AM; Yang D; Groshen S; Hendifar AE; Husain H; Gordon MA; Nagashima F; Chang HM; Lenz HJ Ann Oncol; 2008 Oct; 19(10):1734-41. PubMed ID: 18550579 [TBL] [Abstract][Full Text] [Related]
7. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. Sinicrope FA; Foster NR; Thibodeau SN; Marsoni S; Monges G; Labianca R; Kim GP; Yothers G; Allegra C; Moore MJ; Gallinger S; Sargent DJ J Natl Cancer Inst; 2011 Jun; 103(11):863-75. PubMed ID: 21597022 [TBL] [Abstract][Full Text] [Related]
8. The cyclin D1 (CCND1) rs9344 G>A polymorphism predicts clinical outcome in colon cancer patients treated with adjuvant 5-FU-based chemotherapy. Absenger G; Benhaim L; Szkandera J; Zhang W; Yang D; Labonte MJ; Pichler M; Stotz M; Samonigg H; Renner W; Gerger A; Lenz HJ Pharmacogenomics J; 2014 Apr; 14(2):130-4. PubMed ID: 23567490 [TBL] [Abstract][Full Text] [Related]
9. Preoperative Serum Carcinoembryonic Antigen Level as a Prognostic Factor for Recurrence and Survival After Curative Resection Followed by Adjuvant Chemotherapy in Stage III Colon Cancer. Kim CG; Ahn JB; Jung M; Beom SH; Heo SJ; Kim JH; Kim YJ; Kim NK; Min BS; Koom WS; Kim H; Roh YH; Ma BG; Shin SJ Ann Surg Oncol; 2017 Jan; 24(1):227-235. PubMed ID: 27699609 [TBL] [Abstract][Full Text] [Related]
10. Gene-expression signature of tumor recurrence in patients with stage II and III colon cancer treated with 5'fluoruracil-based adjuvant chemotherapy. Giráldez MD; Lozano JJ; Cuatrecasas M; Alonso-Espinaco V; Maurel J; Mármol M; Hörndler C; Ortego J; Alonso V; Escudero P; Ramírez G; Petry C; Lasalvia L; Bohmann K; Wirtz R; Mira A; Castells A Int J Cancer; 2013 Mar; 132(5):1090-7. PubMed ID: 22833293 [TBL] [Abstract][Full Text] [Related]
11. LINE-1 Methylation Status Correlates Significantly to Post-Therapeutic Recurrence in Stage III Colon Cancer Patients Receiving FOLFOX-4 Adjuvant Chemotherapy. Lou YT; Chen CW; Fan YC; Chang WC; Lu CY; Wu IC; Hsu WH; Huang CW; Wang JY PLoS One; 2014; 10(4):e0123973. PubMed ID: 25919688 [TBL] [Abstract][Full Text] [Related]
12. LGR5 rs17109924 is a predictive genetic biomarker for time to recurrence in patients with colon cancer treated with 5-fluorouracil-based adjuvant chemotherapy. Szkandera J; Herzog S; Pichler M; Stiegelbauer V; Stotz M; Schaberl-Moser R; Samonigg H; Asslaber M; Lax S; Leitner G; Renner W; Lenz HJ; Berghold A; Gerger A Pharmacogenomics J; 2015 Oct; 15(5):391-6. PubMed ID: 25665511 [TBL] [Abstract][Full Text] [Related]
13. Cancer Stem Cell Gene Variants in CD44 Predict Outcome in Stage II and Stage III Colon Cancer Patients. Stotz M; Herzog SA; Pichler M; Smolle M; Riedl J; Rossmann C; Bezan A; Stöger H; Renner W; Berghold A; Gerger A Anticancer Res; 2017 Apr; 37(4):2011-2018. PubMed ID: 28373475 [TBL] [Abstract][Full Text] [Related]
14. Plastin3 is a novel marker for circulating tumor cells undergoing the epithelial-mesenchymal transition and is associated with colorectal cancer prognosis. Yokobori T; Iinuma H; Shimamura T; Imoto S; Sugimachi K; Ishii H; Iwatsuki M; Ota D; Ohkuma M; Iwaya T; Nishida N; Kogo R; Sudo T; Tanaka F; Shibata K; Toh H; Sato T; Barnard GF; Fukagawa T; Yamamoto S; Nakanishi H; Sasaki S; Miyano S; Watanabe T; Kuwano H; Mimori K; Pantel K; Mori M Cancer Res; 2013 Apr; 73(7):2059-69. PubMed ID: 23378342 [TBL] [Abstract][Full Text] [Related]
15. Identification of polymorphisms in ultraconserved elements associated with clinical outcomes in locally advanced colorectal adenocarcinoma. Lin M; Eng C; Hawk ET; Huang M; Lin J; Gu J; Ellis LM; Wu X Cancer; 2012 Dec; 118(24):6188-98. PubMed ID: 22673945 [TBL] [Abstract][Full Text] [Related]
16. Relationship Between Metformin Use and Recurrence and Survival in Patients With Resected Stage III Colon Cancer Receiving Adjuvant Chemotherapy: Results From North Central Cancer Treatment Group N0147 (Alliance). Singh PP; Shi Q; Foster NR; Grothey A; Nair SG; Chan E; Shields AF; Goldberg RM; Gill S; Kahlenberg MS; Sinicrope FA; Sargent DJ; Alberts SR Oncologist; 2016 Dec; 21(12):1509-1521. PubMed ID: 27881709 [TBL] [Abstract][Full Text] [Related]
17. Gender-specific profiling in SCN1A polymorphisms and time-to-recurrence in patients with stage II/III colorectal cancer treated with adjuvant 5-fluoruracil chemotherapy. Benhaim L; Gerger A; Bohanes P; Paez D; Wakatsuki T; Yang D; Labonte MJ; Ning Y; El-Khoueiry R; Loupakis F; Zhang W; Laurent-Puig P; Lenz HJ Pharmacogenomics J; 2014 Apr; 14(2):135-41. PubMed ID: 23752739 [TBL] [Abstract][Full Text] [Related]
18. Association of common gene variants in the WNT/β-catenin pathway with colon cancer recurrence. Páez D; Gerger A; Zhang W; Yang D; Labonte MJ; Benhanim L; Kahn M; Lenz F; Lenz C; Ning Y; Wakatsuki T; Loupakis F; Lenz HJ Pharmacogenomics J; 2014 Apr; 14(2):142-50. PubMed ID: 23817222 [TBL] [Abstract][Full Text] [Related]
19. Associations between cigarette smoking status and colon cancer prognosis among participants in North Central Cancer Treatment Group Phase III Trial N0147. Phipps AI; Shi Q; Newcomb PA; Nelson GD; Sargent DJ; Alberts SR; Limburg PJ J Clin Oncol; 2013 Jun; 31(16):2016-23. PubMed ID: 23547084 [TBL] [Abstract][Full Text] [Related]
20. Girdin (GIV) Expression as a Prognostic Marker of Recurrence in Mismatch Repair-Proficient Stage II Colon Cancer. Ghosh P; Tie J; Muranyi A; Singh S; Brunhoeber P; Leith K; Bowermaster R; Liao Z; Zhu Y; LaFleur B; Tran B; Desai J; Jones I; Croxford M; Jover R; Goel A; Waring P; Hu S; Teichgraber V; Rohr UP; Ridder R; Shanmugam K; Gibbs P Clin Cancer Res; 2016 Jul; 22(14):3488-98. PubMed ID: 27029492 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]